Views & Analysis Q&A: Fortress Biotech’s Lindsay Rosenwald on breathing new l... One downside of the explosion in our knowledge about potential drug targets is that many promising candidates are getting left on the backburner.
News AZ prepares to file blood pressure drug after trial win Two years after buying CinCor for $1.3 billion, AstraZeneca has reported that the main asset in the deal has cleared a phase 3 trial.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face